Biogen (BIIB)
(Delayed Data from NSDQ)
$131.95 USD
+3.95 (3.09%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $131.93 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIIB 131.95 +3.95(3.09%)
Will BIIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Other News for BIIB
Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio
RBC Capital Boosts Biogen (BIIB) Price Target After Strong Q2 Earnings
RBC Capital Raises Price Target for Biogen (BIIB) to $219 | BIIB Stock News
Biogen (BIIB) Price Target Adjusted Amid Growth Concerns